🔗 Share this article

As the US undertakes historic revisions to its vaccine recommendations, an unexpected name appears somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning coronavirus shots during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her brief time at the FDA.

Planned Shifts to Pediatric Immunization Schedule

Public health authorities planned to unveil radical revisions to the childhood immunization program in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of step with a large portion of the global community with no evidence for public health gain. This reveal has been postponed until the new year.

In place of the top vaccines chief, Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to head the center this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccination policy – usually the purview of Dr. Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

Høeg has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been typical for past leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who headed the center have had.”

CDER has an immense portfolio at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the off-patent medication office clears thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one have to be supervised,” Dr. Woodcock noted. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative component to the job, which oversees over 5,000 employees. “It is a huge leadership role, if you do it right,” she said.

Response and Contentious Policies

When asked about questions about Høeg’s credentials and whether this selection signifies greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions rely on flawed presumptions”.

“This background aligns with the functions of her job,” the spokesperson stated, citing the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid medication authorization process that reportedly troubled her predecessors. “By what process are these therapies being picked for this voucher program? Who makes the choices?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards less stringent regulations of most medications, with the exception of immunizations.”

Established Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, past, critics have noted. She released a research paper using unverified crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the incoming government included altering regulations for novel immunizations and halting “unnecessary” vaccines, she stated after the election on a audio program. At the FDA, Høeg has allegedly floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She is an all-around true believer who commences with her conclusions and reverse-engineers to fit the evidence in a highly misleading, untruthful way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|